 | Up a level |
Studt, J-D; Alberio, L; Angelillo, Anne; Asmis, L M; Fontana, P; Korte, W; Mendez, A; Schmid, P; Stricker, H; Tsakiris, D A; Wuillemin, W A; Nagler, Michael (2017). Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels. Journal of thrombosis and haemostasis, 15(8), pp. 1576-1583. Wiley-Blackwell 10.1111/jth.13747
Spirk, David; Nendaz, M; Aujesky, Drahomir; Hayoz, D; Beer, J H; Husmann, M; Frauchiger, B; Korte, W; Wuillemin, Walter Alfred; Righini, M; Bounameaux, H; Kucher, Nils (2015). Predictors of thromboprophylaxis in hospitalised medical patients. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). Thrombosis and haemostasis, 113(5), pp. 1127-1134. Schattauer 10.1160/TH14-06-0525
Spirk, D; Ugi, J; Korte, W; Husmann, M; Hayoz, D; Baldi, T; Frauchiger, B; Banyai, M; Aujesky, D; Baumgartner, I; Kucher, N (2011). Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II. Thrombosis and haemostasis, 105(6), pp. 962-7. Stuttgart: Schattauer 10.1160/TH11-01-0002
Asmis, L M; Alberio, L; Angelillo-Scherrer, A; Korte, W; Mendez, A; Reber, G; Seifert, B; Stricker, H; Tsakiris, D A; Wuillemin, W A (2011). Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories. Thrombosis research, 129(4), pp. 492-498. Amsterdam: Elsevier 10.1016/j.thromres.2011.06.031
Kucher, N; Spirk, D; Baumgartner, I; Mazzolai, L; Korte, W; Nobel, D; Banyai, M; Bounameaux, H (2010). Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Annals of oncology, 21(5), pp. 931-5. Oxford: Oxford University Press 10.1093/annonc/mdp406
